What Investors Didn't Like About Co-Diagnostics' Q4 Update
No one expected Co-Diagnostics (NASDAQ: CODX) to follow up its fantastic gain of nearly 940% in 2020 with anything close to that level this year. However, the molecular-diagnostics stock got off to a great start. The momentum is losing steam now, though.
Co-Diagnostics announced its fourth-quarter and full-year 2020 results after the market close on Thursday. The healthcare stock sank 8% in after-hours trading. Here are the highlights from the company's Q4 update.
Image source: Getty Images.
Source Fool.com
